New drug RPH-002 tested against standard therapy for head and neck cancer
Disease control
Completed
This study tested a new drug called RPH-002 against the standard drug Erbitux in 118 people with advanced head and neck cancer that could not be removed by surgery. The main goals were to compare how the drugs move through the body and to check their safety when used with chemoth…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC